KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

Vicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, Erika Hamilton, Toon Van Gorp, Jalid Sehouli, Klaudia Regináčová, Debra L Richardson, Tamar Perri, Amit M Oza, David S Miller, Eva Maria Guerra Alía, Ugo De Giorgi, Stephanie Henry, Daniel L Spitz, Pauline Wimberger, Markéta Bednaříková, Hye Sook Chon, Jerónimo Martínez-Garcia, Carmela Pisano, Jonathan S Berek, Ignacio Romero, Giovanni Scambia, Lorena Fariñas-Madrid, Joseph Buscema, Fabienne Schochter, Kai Li, Pratheek Kalyanapu, Christopher J Walker, Ignace Vergote

Gynecol Oncol 185 202-211

PMID38834399
PMCIDPMC12903923
DOI10.1016/j.ygyno.2024.05.016
发表日期2024-06-04
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVE: To report long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or complete remission (CR) following chemotherapy. METHODS: Analysis of the prespecified, exploratory subgroup of patients with TP53wt EC from the phase 3 SIENDO study was performed. Progression-free survival (PFS) benefit in patients with TP53wt EC and across other patient subgroups were exploratory endpoints. Safety and tolerability were also assessed. RESULTS: Of the 263 patients enrolled in the SIENDO trial, 113 patients had TP53wt EC; 70/113 (61.9%) had TP53wt/proficient mismatch repair (pMMR) EC, and 29/113 (25.7%) had TP53wt/deficient mismatch repair (dMMR) EC. As of April 1, 2024, the median PFS (mPFS) for TP53wt patients who received selinexor compared with placebo was 28.4 versus 5.2 months (36.8-month follow-up, HR 0.44; 95% CI 0.27-0.73). A benefit in mPFS was seen with selinexor versus placebo regardless of MMR status (patients with TP53wt/pMMR EC: 39.5 vs 4.9 months, HR 0.36; 95% CI 0.19-0.71; patients with TP53wt/dMMR EC: 13.1 vs 3.7 months, HR 0.49; 95% CI 0.18-1.34). Selinexor treatment was generally manageable, with no new safety signals identified. CONCLUSION: In the phase 3 SIENDO study, selinexor maintenance therapy showed a promising efficacy signal and a manageable safety profile in the prespecified subgroup of patients with TP53wt EC who achieved a PR or CR following chemotherapy. These results are being further evaluated in an ongoing randomized phase 3 trial (NCT05611931).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。